Lilly’s poor run continues as Alimta fails in lung cancer
Phase III trial comparing it to Roche’s Avastin misses primary endpoint
Read More
Section: Research
AstraZeneca drops Palatin’s obesity drug after trial subject suffers allergic reaction
But collaboration with the US biotech remains in place
Read More
Merck KGaA acquires cancer drug from Symphogen
Will pay up to €495m for investigational metastatic colorectal cancer treatment
Read More
Roche says pipeline will balance cancer drug patent losses
Has 11 new molecular entities in late-stage portfolio and 11 line extensions
Read MoreINC Research promotes Susan Akers-Smith to senior oncology role
She takes up the position of VP of early phase oncology development
Read More